Companies › PYC Therapeutics
3 active drug programs in 4 registered trials: 4 Phase 1; Ophthalmology, Genitourinary; next expected readout Mar 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| VP-001 Oligonucleotide-peptide conjugate targeting PRPF31 mutation | PRPF31 | Phase 1 | Retinitis Pigmentosa 11 | Mar 2028 |
| PYC-003 Peptide-phosphorodiamidate morpholino oligonucleotide conjugate targeting PKD1 | PKD1 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Nov 2028 |
| PYC-001 Peptide-phosphorodiamidate morpholino oligonucleotide (PMO) targeting OPA1 | OPA1 | Phase 1 | OPA1 Gene Mutation | Oct 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06852963 | VP-001 | Phase 1 | Retinitis Pigmentosa 11 | Ophthalmology | Mar 2028 |
| NCT06714006 | PYC-003 | Phase 1 | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Genitourinary | Nov 2028 |
| NCT06461286 | PYC-001 | Phase 1 | OPA1 Gene Mutation | Ophthalmology | Oct 2029 |
| NCT06970106 | PYC-001 | Phase 1 | OPA1 Gene Mutation | Ophthalmology | Oct 2029 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.